漢達生技

漢達生技 https://validator.w3.org/feed/docs/rss2.html Financials 財務資訊重要公司規章 Material Information- Announcement of the Board’s Resolution to release the non-competition restriction on managerial officers Material Information- Announcement of the Board’s Resolution to redeem and cancel restricted employee shares for a capital reduction Material Information- Clarification of Media Report 重大訊息-澄清媒體報導 Material Information- Announcement of the Board of Directors approved the consolidated financial statements for 2026 Q1. Material Information- Announcement of the expected date of the Board Meeting to approve 2026 Q1 Financial Report on May 7, 2026 重大訊息-本公司董事會通過解除經理人競業禁止之限制案 Management Team Company Profile 公司基本資料經營團隊重大訊息-公告本公司董事會決議辦理限制員工權利新股收回註銷減資事宜重大訊息-公告本公司董事會通過115年第一季合併財務報告重大訊息-公告本公司115年第一季財務報告董事會預計召開日期為115年5月7日 Material Information- Announces on behalf of the subsidiary Handa Oncology, LLC, regarding the 505(b)(2) new formulation drug HND-039 citizen petition to the FDA examination 重大訊息-代子公司Handa Oncology, LLC公告505(b)(2)新藥HND-039美國FDA藥品審查訴願案獨立董事與內部稽核主管及會計師之溝通情形 Company Overview 公司簡介 Stakeholder 利害關係人專區 Major Internal Policies Material Information- Correction to the Material Information announced on March 12, 2026: Announcement of the newly appointed Chief Innovation Officer Material Information- Announcement of the newly appointed Chief Innovation Officer Material Information- Announcement of the Board’s Resolution to Repurchase Treasury Shares Material Information- Announcement of the Completion of the Company’s Treasury Share Buyback 重大訊息-公告本公司董事會決議買回庫藏股事宜重大訊息-公告本公司買回庫藏股執行完畢法說會資訊 Material Information- The Company was invited to attend the in-person and virtual institutional investor conference hosted by First Securities 重大訊息-本公司受邀參加第一金證券舉辦之實體暨線上法人說明會 Material Information- Announcement of the change of internal audit officer Material Information- To convene the 2026 annual shareholders’ meeting. Material Information- Announcement of the Board Resolution on Distribution of Dividends Material Information- The Board of Directors Approved the 2025 Consolidated Financial Statements Material Information- Announcement of the expected date of the Board Meeting to approve 2025 Annual Financial Report on March 12, 2026 Material Information- Announcement of the Board’s Resolution to Repurchase Treasury Shares 重大訊息- 公告本公司內部稽核主管異動重大訊息- 公告本公司新任創新長重大訊息- 更正本公司115年3月12日發布之重大訊息「公告本公司新任創新長」之部分內容重大訊息- 公告召開本公司115年股東常會重大訊息- 本公司董事會決議分派股利重大訊息- 公告本公司董事會通過114年度合併財務報告重大訊息- 公告本公司114年度財務報告董事會預計召開日期為115年3月12日重大訊息- 公告本公司董事會決議買回庫藏股事宜 Material Information-Announcement of Stabilization Operation Results during the First Five Trading Days after the Company’s Initial Taipei Exchange Listing 首頁